Arya Consulting Partners announced the release of Rare Disease Pricing & Access: Navigating Value, Evidence, and Sustainability, the second installment in the firm’s Rare Disease white paper series.

The white paper examines the unique pricing and market access challenges facing rare disease therapies as payer scrutiny intensifies globally. It explores how manufacturers can balance premium pricing expectations with growing demands for robust clinical, economic, and real‑world evidence across increasingly complex access environments.